Cronos Group (CRON) Aktienübersicht
Cronos Group Inc. ist ein Cannabinoid-Unternehmen, das sich mit dem Anbau, der Produktion, dem Vertrieb und der Vermarktung von Cannabisprodukten in Kanada, Israel und auf internationaler Ebene beschäftigt. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 2/6 |
| Künftiges Wachstum | 4/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 6/6 |
| Dividenden | 0/6 |
Belohnungen
Risikoanalyse
Bei unseren Risikoprüfungen wurden keine Risiken für CRON festgestellt.
CRON Community Fair Values
Create NarrativeSee what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Cronos Group Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | CA$3.77 |
| 52-Wochen-Hoch | CA$4.66 |
| 52-Wochen-Tief | CA$2.54 |
| Beta | 1.23 |
| 1 Monat Veränderung | 3.57% |
| 3 Monate Veränderung | 4.14% |
| 1 Jahr Veränderung | 35.13% |
| 3 Jahre Veränderung | 58.40% |
| 5 Jahre Veränderung | -65.12% |
| Veränderung seit IPO | 354.22% |
Aktuelle Nachrichten und Updates
Narrativ-Update • May 12
CRON: Partial Rescheduling And Brand Execution Will Shape Lean Profit Outlook
Analysts have lifted their fair value estimate for Cronos Group from CA$3.19 to CA$3.45, citing recent initiation with a CA$4.50 price target and the view that branded positioning, a lean cost base, and potentially favorable regulatory shifts could support higher long term profitability and a lower future P/E assumption. Analyst Commentary Recent commentary around Cronos Group has focused on brand strength, cost discipline, and the potential impact of regulatory changes in key markets.Narrativ-Update • Apr 25
CRON: Partial Rescheduling Hopes Will Test Lean Cost Base Execution
Analysts have raised their Cronos Group price target to CA$4.50, citing expectations for slightly stronger revenue growth, modestly better profit margins, and a lower assumed future P/E, following recent bullish coverage and a favorable view on partial cannabis rescheduling. Analyst Commentary Recent research coverage on Cronos Group has centered on how potential regulatory shifts and brand positioning could influence the company’s path to improved profitability and valuation.
Narrativ-Update • Apr 11
CRON: Canadian Brand Strength And Lean Cost Base Will Support Future Upside
Analysts have reset their price target for Cronos Group to CA$4.50, reflecting fresh coverage that highlights the company’s established Canadian brands, its focus on scaling revenue with a lean cost base, and cultivation practices that are expected to support profitability trends. Analyst Commentary Recent coverage frames Cronos Group as a company with established Canadian brands and a focus on keeping its cost base lean while scaling revenue.Recent updates
Narrativ-Update • May 12
CRON: Partial Rescheduling And Brand Execution Will Shape Lean Profit Outlook
Analysts have lifted their fair value estimate for Cronos Group from CA$3.19 to CA$3.45, citing recent initiation with a CA$4.50 price target and the view that branded positioning, a lean cost base, and potentially favorable regulatory shifts could support higher long term profitability and a lower future P/E assumption. Analyst Commentary Recent commentary around Cronos Group has focused on brand strength, cost discipline, and the potential impact of regulatory changes in key markets.Narrativ-Update • Apr 25
CRON: Partial Rescheduling Hopes Will Test Lean Cost Base Execution
Analysts have raised their Cronos Group price target to CA$4.50, citing expectations for slightly stronger revenue growth, modestly better profit margins, and a lower assumed future P/E, following recent bullish coverage and a favorable view on partial cannabis rescheduling. Analyst Commentary Recent research coverage on Cronos Group has centered on how potential regulatory shifts and brand positioning could influence the company’s path to improved profitability and valuation.Narrativ-Update • Apr 11
CRON: Canadian Brand Strength And Lean Cost Base Will Support Future Upside
Analysts have reset their price target for Cronos Group to CA$4.50, reflecting fresh coverage that highlights the company’s established Canadian brands, its focus on scaling revenue with a lean cost base, and cultivation practices that are expected to support profitability trends. Analyst Commentary Recent coverage frames Cronos Group as a company with established Canadian brands and a focus on keeping its cost base lean while scaling revenue.Narrativ-Update • Mar 28
CRON: Lean Cost Base And Brand Execution Will Shape Future Earnings Potential
Analysts have lifted their average price target for Cronos Group to CA$4.50, citing expectations for faster top line expansion, a leaner cost base and stronger profitability potential supported by the company's established Canadian cannabis brands and cultivation practices. Analyst Commentary Recent Street research has framed Cronos Group as a branded cannabis operator with established products in Canada and an emphasis on scaling revenue while keeping operating costs in check.Narrativ-Update • Mar 13
CRON: Canadian Brand Strength And Rescheduling Shift Will Support Future Upside
Analysts have lifted their CA$ price target on Cronos Group, citing the company's Canadian cannabis brands, expectations for better profitability as revenue grows against a lean cost base, and confidence in its cultivation practices as key supports for the higher valuation range. Analyst Commentary Bullish Takeaways Bullish analysts highlight Cronos Group's portfolio of Canadian cannabis brands as a key support for the higher CA$ valuation range, arguing that strong consumer recognition can help sustain revenue as the company scales.Narrativ-Update • Feb 27
CRON: Canadian Brand Strength And Rescheduling Shift Will Reshape Risk Reward Profile
Analysts have lifted their fair value estimate for Cronos Group to CA$4.24 from CA$3.95, pointing to higher assumed revenue growth and a lower future P/E multiple. They are factoring in recent bullish coverage highlighting the company’s established Canadian cannabis brands, lean cost base, and cultivation practices.Narrativ-Update • Feb 13
CRON: Rescheduling Shift Will Expose Execution Risks And Restrain Earnings Upside
Analysts have lifted their CA$ fair value estimate for Cronos Group to CA$3.19, citing Street research that points to slightly higher expected revenue growth, modestly stronger profit margins, and a marginally lower future P/E assumption that together support a more constructive long term outlook. Analyst Commentary While the higher CA$3.19 fair value estimate reflects a more constructive stance on Cronos Group, not all research is leaning in the same direction.Narrativ-Update • Jan 30
CRON: Rescheduling Shift And Product Expansion Will Shape A Balanced Earnings Outlook
Analysts have raised their price target on Cronos Group by a small amount to reflect updated assumptions for slightly higher revenue growth, a modestly stronger profit margin, and a marginally higher future P/E multiple. Analyst Commentary While some research points to a constructive view on Cronos Group, bearish analysts highlight a set of risks that could limit upside and keep the stock more range bound.Narrativ-Update • Jan 16
CRON: Rescheduling Policy Shift Will Temper Optimism On Future Earnings Profile
Analysts have raised their price target for Cronos Group to US$3.19 from US$2.90, pointing to updated assumptions around slightly higher discount rates, more conservative revenue growth and a modestly stronger profit margin profile, alongside a similar forward P/E outlook. What's in the News President Trump directed the Attorney General to complete the rulemaking process to reschedule marijuana to Schedule III of the Controlled Substances Act, which directly touches U.S. cannabis policy and mentions Cronos Group among other publicly traded peers in the sector (Marijuana Herald).Analyseartikel • Dec 13
Cronos Group Inc. (TSE:CRON) Stock Rockets 29% As Investors Are Less Pessimistic Than Expected
Cronos Group Inc. ( TSE:CRON ) shareholders have had their patience rewarded with a 29% share price jump in the last...Narrativ-Update • Sep 04
GrowCo Capacity And Global Markets Will Unlock Potential
The Consensus Analyst Price Target for Cronos Group has increased to CA$3.95, primarily reflecting a notable rise in the company's Future P/E multiple despite stable revenue growth expectations. What's in the News President Trump is considering reclassifying marijuana as a less dangerous drug, which could ease restrictions and benefit cannabis companies such as Cronos Group (The Wall Street Journal).Analyseartikel • Aug 15
Cronos Group Inc.'s (TSE:CRON) 26% Share Price Surge Not Quite Adding Up
Cronos Group Inc. ( TSE:CRON ) shareholders would be excited to see that the share price has had a great month, posting...
Neues Narrativ • Apr 30
GrowCo Expansion Will Boost Operations But Strain Cash Flow
Investment in GrowCo and advancements in cannabis genetics are set to improve efficiency, enhance profitability, and strengthen market penetration.Analyseartikel • May 31
We're Interested To See How Cronos Group (TSE:CRON) Uses Its Cash Hoard To Grow
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analyseartikel • Apr 01
Cronos Group Inc.'s (TSE:CRON) P/S Is Still On The Mark Following 29% Share Price Bounce
The Cronos Group Inc. ( TSE:CRON ) share price has done very well over the last month, posting an excellent gain of...Analyseartikel • Mar 02
We Think Cronos Group (TSE:CRON) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analyseartikel • Feb 02
Revenues Tell The Story For Cronos Group Inc. (TSE:CRON)
When you see that almost half of the companies in the Pharmaceuticals industry in Canada have price-to-sales ratios (or...Analyseartikel • Nov 09
Companies Like Cronos Group (TSE:CRON) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analyseartikel • Jul 17
We're Hopeful That Cronos Group (TSE:CRON) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although...Analyseartikel • Jun 20
Cronos Group Inc.'s (TSE:CRON) Earnings Haven't Escaped The Attention Of Investors
When you see that almost half of the companies in the Pharmaceuticals industry in Canada have price-to-sales ratios (or...Aktionärsrenditen
| CRON | CA Pharmaceuticals | CA Markt | |
|---|---|---|---|
| 7D | 4.4% | 1.3% | 1.6% |
| 1Y | 35.1% | 45.3% | 33.7% |
Rendite im Vergleich zur Industrie: CRON unter dem Niveau der Branche Canadian Pharmaceuticals , die im vergangenen Jahr eine Rendite von 45.3% erzielte.
Rendite vs. Markt: CRON übertraf den Markt Canadian, der im vergangenen Jahr eine Rendite von 33.7 erzielte.
Preisvolatilität
| CRON volatility | |
|---|---|
| CRON Average Weekly Movement | 5.8% |
| Pharmaceuticals Industry Average Movement | 11.6% |
| Market Average Movement | 10.2% |
| 10% most volatile stocks in CA Market | 17.9% |
| 10% least volatile stocks in CA Market | 3.9% |
Stabiler Aktienkurs: CRON hatte in den letzten 3 Monaten im Vergleich zum Canadian -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: CRONDie wöchentliche Volatilität (6%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| n/a | 610 | Mike Gorenstein | thecronosgroup.com |
Cronos Group Inc. ist ein Cannabinoid-Unternehmen, das sich mit dem Anbau, der Produktion, dem Vertrieb und der Vermarktung von Cannabisprodukten in Kanada, Israel und international beschäftigt. Es bietet getrocknete Blüten, Pre-Rolls, Öle, Verdampfer, Esswaren und Cannabis-Tinkturen unter den Markennamen Spinat, Lord Jones und PEACE NATURALS an. Der Sitz des Unternehmens befindet sich in Stayner, Kanada.
Cronos Group Inc.'s Grundlagenzusammenfassung
| CRON grundlegende Statistiken | |
|---|---|
| Marktanteil | CA$1.42b |
| Gewinn(TTM) | -CA$13.05m |
| Umsatz(TTM) | CA$202.50m |
7.0x
Kurs-Umsatz-Verhältnis-108.7x
Kurs-Gewinn-Verhältnis Ist CRON zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| CRON Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$146.59m |
| Kosten der Einnahmen | US$88.19m |
| Bruttogewinn | US$58.40m |
| Sonstige Ausgaben | US$67.85m |
| Gewinn | -US$9.45m |
Zuletzt gemeldete Gewinne
Dec 31, 2025
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -0.025 |
| Bruttomarge | 39.84% |
| Nettogewinnspanne | -6.44% |
| Schulden/Eigenkapital-Verhältnis | 0% |
Wie hat sich CRON auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/24 01:59 |
| Aktienkurs zum Tagesende | 2026/05/22 00:00 |
| Gewinne | 2025/12/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Cronos Group Inc. wird von 16 Analysten beobachtet. 4 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Jesse Pytlak | ATB Cormark Historical (Cormark Securities) |
| Vahan Ajamian | Beacon Securities Limited |
| Nadine Sarwat | Bernstein |